Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

The tumor microenvironment (TME) has been identified as one of the driving factors of tumor
progression and invasion. Within this microenvironment, cancer‐associated fibroblasts …

Recent single-cell studies of cancer in both mice and humans have identified the
emergence of a myofibroblast population specifically marked by the highly restricted leucine …

Cancer treatment continues to shift from utilizing traditional therapies to targeted ones, such
as protein kinase inhibitors and immunotherapy. Mobilizing dendritic cells (DC) and other …

The theory that cancer-associated fibroblasts (CAFs) are immunosuppressive cells has
prevailed throughout the past decade. However, recent high-throughput, high-resolution …

Cancer immunotherapies have rapidly changed the therapeutic landscape for cancer.
Nevertheless, most of the patients show innate or acquired resistance to these therapies …

T cells are often absent from human cancer tissues during both spontaneously induced
immunity and therapeutic immunotherapy, even in the presence of a functional T cell …

Non–small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths. Immune
checkpoint blockade has improved survival for many patients with NSCLC, but most fail to …

Introduction Tumour-reactive T cells producing the B-cell attractant chemokine CXCL13, in
solid tumours, promote development of tertiary lymphoid structures (TLS) and are associated …

Microenvironmental bystander cells are essential for the progression of chronic lymphocytic
leukemia (CLL). We have discovered previously that LYN kinase promotes the formation of a …